• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Abbott to develop biowearable for continuous monitoring of glucose, ketone levels

June 3, 2022 By Sean Whooley

Abbott logo updatedAbbott (NYSE:ABT) announced today that it is developing a new biowearable for continuously monitoring both glucose and ketone levels.

The all-in-one sensor has already garnered FDA breakthrough device designation and will be used in pivotal trials in 2023, with regulatory submissions to follow thereafter.

Abbott Park, Illinois-based Abbott said in a news release that the glucose-ketone sensor will be the same size as the recently FDA-cleared next-generation FreeStyle Libre 3 continuous glucose monitoring (CGM) sensor, and it will connect to Abbott’s digital ecosystem that includes personal and caregiver mobile apps along with cloud-based data management software for remote monitoring by healthcare professionals.

The company also plans to partner with leading insulin pump manufacturers to make the new biowearable sensor interoperable with insulin delivery systems.

“Abbott revolutionized diabetes care with FreeStyle Libre technology, which is the number one continuous glucose monitor used by 4 million people around the world,” SVP of Abbott’s diabetes care business Jared Watkin said in the release. “We’re designing our glucose-ketone monitoring system with superior sensing technology that will pair with industry-leading insulin pumps to create a best-in-class solution. We’re optimistic that this will be the next big advancement in diabetes tech and a breakthrough for people with diabetes, especially those who are at risk of developing diabetic ketoacidosis (DKA).”

The company said a continuous glucose-ketone monitor represents an important tool for people with diabetes who may be at higher risk of developing DKA, a potentially life-threatening condition when ketone levels rise to dangerous heights in the blood. The combination sensor would eliminate the need for a separate ketone test to accompany CGM.

“In my practice, I’ve seen numerous cases of DKA in teens and children, which could have been prevented with continuous ketone monitoring,” Midwest Pediatric Specialists (Overland Park, Kansas) Medical Director and pediatric endocrinologist Dr. Kurt Midyett said. “Bringing people with diabetes the ability to continuously monitor both glucose and ketones in a single, intuitive device is an important step forward in diabetes care, as it will allow patients to detect rising ketone levels and intervene before full-blown DKA develops.”

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Patient Monitoring, Pediatrics, Regulatory/Compliance Tagged With: abbott

IN CASE YOU MISSED IT

  • Retractable Technologies declares dividends
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • West Pharmaceutical Services debuts new needle syringe system
  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS